-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 10, China's National Food and Drug Administration (NMPA) recently announced that Hengrui Medicine's PD-1 inhibitor carrelizumab has been approved for the marketing of two new indications
Screenshot source: NMPA official website
Carrelizumab for injection is a humanized anti-PD-1 monoclonal antibody independently developed by Hengrui Pharmaceuticals, which can bind to human PD-1 receptors and block the PD-1/PD-L1 pathway to restore the body’s Anti-tumor immunity, thus forming the basis of cancer immunotherapy